Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Eva Versteijne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3861-5310; OpenAlex author ID A5002147373. Sources: OpenAlex.

Their work

Papers
26 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 5 papers · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 26

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  3. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  4. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  5. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  6. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  7. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Co-author DOI 10.1016/j.annonc.2024.05.003↗
  8. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. Last author DOI 10.1016/j.ijrobp.2023.08.055↗
  9. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-05219-7↗
  10. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. First author DOI 10.1016/j.ejso.2022.12.011↗
  11. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  12. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  13. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Co-author DOI 10.3389/fonc.2023.1149961↗
  14. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderl… Co-author DOI 10.1097/sla.0000000000004313↗
  15. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Pat… Co-author DOI 10.1097/sla.0000000000004364↗
  16. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Co-author DOI 10.1186/s12885-022-10419-4↗
  17. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  18. Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy? Co-author DOI 10.3389/fonc.2021.744161↗
  19. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  20. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  21. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1002/bjs.10870↗
  22. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. First author DOI 10.1080/02656736.2017.1401126↗
  23. Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run. Co-author DOI 10.1007/s00066-017-1153-6↗
  24. Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study. Co-author DOI 10.1186/s13014-017-0777-0↗
  25. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multi… First author DOI 10.1186/s13063-016-1262-z↗
  26. Dosimetric Advantages of Midventilation Compared With Internal Target Volume for Radiation Therapy of Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.02.015↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geertjan van Tienhoven · 19 shared papers, 2015–2025 · strength 2.11
  2. Marc G. Besselink · 15 shared papers, 2016–2025 · strength 1.86
  3. Johanna W. Wilmink · 12 shared papers, 2018–2025 · strength 1.55
  4. Casper H.J. van Eijck · 13 shared papers, 2016–2025 · strength 1.41
  5. Bas Groot Koerkamp · 9 shared papers, 2018–2025 · strength 1.07
  6. Ignace H. J. T. de Hingh · 9 shared papers, 2016–2025 · strength 1.04
  7. Anna M E Bruynzeel · 6 shared papers, 2022–2025 · strength 0.99
  8. Joost J.M.E. Nuyttens · 7 shared papers, 2020–2025 · strength 0.93
  9. Bert A. Bonsing · 8 shared papers, 2016–2025 · strength 0.90
  10. Mustafa Suker · 8 shared papers, 2016–2023 · strength 0.82
  11. Gijs A. Patijn · 7 shared papers, 2016–2025 · strength 0.77
  12. Judith de Vos‐Geelen · 7 shared papers, 2016–2025 · strength 0.76
  13. Geert Kazemier M · 5 shared papers, 2022–2025 · strength 0.75
  14. Deesje Doppenberg · 5 shared papers, 2022–2023 · strength 0.73
  15. Hjalmar C. van Santvoort · 5 shared papers, 2021–2025 · strength 0.69
  16. Sebastiaan Festen · 6 shared papers, 2016–2023 · strength 0.62
  17. Marjolein Y.V. Homs · 5 shared papers, 2020–2025 · strength 0.59
  18. Martijn Intven · 4 shared papers, 2021–2025 · strength 0.59
  19. Izaak Quintus Molenaar · 5 shared papers, 2016–2023 · strength 0.57
  20. Martijn Ruben Meijerink · 3 shared papers, 2022–2023 · strength 0.43
  21. Frank J. Lagerwaard · 3 shared papers, 2022–2023 · strength 0.43
  22. J. Sven D. Mieog · 3 shared papers, 2022–2025 · strength 0.42
  23. Jacob L. van Dam · 3 shared papers, 2022–2025 · strength 0.38
  24. Hanneke W.M. van Laarhoven · 3 shared papers, 2018–2023 · strength 0.34
  25. Marion B.M. van der Kolk · 3 shared papers, 2016–2025 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.